Research guide · Recovery & Repair
LL-37 — research protocol
Cathelicidin antimicrobial peptide studied for innate immunity and wound healing.
This guide summarizes study areas and sources associated with the compound. BioPeptideX does not convert experimental information into a clinical regimen or recommend an individual dose, frequency, route or duration.
Catalog presentations
Concentration table
Mathematical reference only; this is not a dosing recommendation.
Research areas
- Cathelicidin peptide
- Antimicrobial
- 99% HPLC purity
Most-cited research protocols
Educational information based on research protocols and literature; it does not replace guidance from a healthcare professional.
LL-37 is the only human cathelicidin antimicrobial peptide. While human clinical trials used it as a topical gel for ulcers, the research community commonly uses a daily subcutaneous protocol that is not trial-validated.
| Dose | Frequency | Duration | Route | |
|---|---|---|---|---|
| Subcutaneous (Community-derived) | 100-200 mcg/day (starting range); Up to 500 mcg/day (upper range cited) | Once daily, often 5 days/week | 2-4 weeks | Subcutaneous injection |
| Topical (Trial context) | 0.5 mg/mL (best healing rate); 1.6 mg/mL (effective); 3.2 mg/mL (first-in-man only) | Twice weekly | Not specified for trials, but healing improved over 4-week and 13-week windows | Topical gel |
Cycle: Short block: 2-3 weeks on, 2+ weeks off. Standard block: 4 weeks on, 2-4 weeks off.
Benefits and research observations: Human trial data showed improved healing over 4-week and 13-week treatment windows for topical application. For injectable use, monitor the injection site, track skin/inflammatory changes, and stop if reactions build.
Handling and storage
Store unreconstituted product according to its label and maintain the cold chain where applicable. After any preparation, follow only validated instructions for the specific product and diluent. Do not use if packaging is damaged or the solution shows particles or unexpected changes.
Warnings
Do not use this page for self-diagnosis or self-medication. Pregnancy, breastfeeding, minors, cancer history, allergies, active disease and concurrent treatments require individual professional evaluation.
Published sources
- 1.Vandamme D, et al. Cell Immunol, 2012.
- 2.Kahlenberg JM, et al. J Immunol, 2013.